| Literature DB >> 34102033 |
Christopher J Yuskaitis1,2,3, Leigh-Ana Rossitto1, Karenna J Groff1, Sameer C Dhamne1, Bo Zhang2,4, Lahin K Lalani1,5, Achint K Singh1,5, Alexander Rotenberg1,2,3,6, Mustafa Sahin1,2,5.
Abstract
OBJECTIVE: To confirm the critical factors affecting seizure susceptibility in acute pentylenetetrazole (PTZ) mouse epilepsy models and evaluate the prior literature for these factors.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34102033 PMCID: PMC8283168 DOI: 10.1002/acn3.51375
Source DB: PubMed Journal: Ann Clin Transl Neurol ISSN: 2328-9503 Impact factor: 4.511
Univariate analysis of factors affecting acute PTZ‐induced seizures in mice.
| GTCS | No GTCS |
| 95% Confidence Interval |
| |
|---|---|---|---|---|---|
| Age | |||||
| Young adult | 34.39% (76/221) | 65.61% (145/221) | ‐0.1261 | ‐0.2379 to ‐0.01104 | 0.027 |
| Mature adult | 13.70% (10/73) | 86.30% (63/73) | |||
| Middle‐aged adult | 69.23% (9/13) | 30.77% (4/13) | |||
| Background Strain | |||||
| C57BL/6J | 29.55% (65/220) | 70.45% (155/220) | 0.04813 | ‐0.06746 to 0.1625 | 0.4 |
| Mixed | 34.48% (30/87) | 65.52% (57/87) | |||
| Sex | |||||
| Male | 30.20% (61/202) | 69.80% (141/202) | 0.02240 | ‐0.09306 to 0.1373 | 0.7 |
| Female | 32.38% (34/105) | 67.62% (71/105) | |||
| Physiologic stress | |||||
| Not present | 26.27% (67/255) | 73.73% (188/255) | 0.2237 | 0.1114 to 0.3304 | <0.0001 |
| Present | 53.85% (28/52) | 46.15% (24/52) | |||
| Dose | |||||
| 40 mg/kg | 18.75% (30/160) | 81.25% (130/160) | 0.2687 | 0.1584 to 0.3724 | <0.0001 |
| 48–50 mg/kg | 53.57% (15/28) | 46.43% (13/28) | |||
| 55–57 mg/kg | 34.92% (22/63) | 65.08% (41/63) | |||
| 65 mg/kg | 50.00% (28/56) | 50.00% (28/56) | |||
Multivariate analysis of factors affecting acute PTZ‐induced seizures in mice.
| Dosage | Factor | Odds ratio | 95% Confidence interval |
|
|---|---|---|---|---|
| All | Dose | 1.149 | 1.102–1.205 | <0.0001 |
| Gender | 0.9512 | 0.5212–1.722 | 0.8692 | |
| Age | 1.1 | 1.041–1.170 | 0.0014 | |
| Physiologic stress | 17.36 | 7.349–44.58 | <0.0001 | |
| Background strain | 0.4725 | 0.2315–0.9345 | 0.0348 | |
| 40 mg/kg | Gender | 0.585 | 0.1293–2.504 | 0.4745 |
| Age | 1.169 | 1.053–1.308 | 0.0038 | |
| Physiologic stress | 60.72 | 15.94–324.0 | <0.0001 | |
| Background strain | 0.2363 | 0.0534–0.8883 | 0.0409 |
Multivariate logistic regression model evaluating the associate between the factors and the likelihood of PTZ‐induced seizures. Total cohort (n = 307) followed by sub‐analysis of only those mice (n = 160) treated with 40 mg/kg PTZ. Odds ratio with associated confidence intervals and p‐values are provided.
FIGURE 1PTZ‐induced seizures are increased with physiologic stressors. Percentage of seizures per group is presented above the bars. **p = 0.003, chi‐square test for trend across the three groups. Mice in the EEG + Isolated cohort have significantly more seizures than the group‐housed cohort as compared by Fisher exact t‐test p = 0.012.
Literature review of factors included in papers using PTZ‐induced acute seizure models in mice.
| Age | Background | Sex | Housing | Dose | GTCS | Other Sz | Death | Sz Features | Sz Scoring | EEG | Threshold | Other | Unclear |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pup | C57BL/6J | Uns. | Group | 40 & 90 mg/kg | + | − | − | − | − | − | − | − | − |
| CD‐1 | Uns. | Uns. | 50 & 100 mg/kg | − | − | − | − | + | − | − | + | − | |
| Juvenile | Albino | M | Uns. | 60 mg/kg | − | − | − | + | + | − | − | − | − |
| Young, uns. | CD‐1 | M | Group | 60 mg/kg | + | − | + | − | + | − | − | − | − |
| Young adult | BALB/c | M | Uns. | 61.96 mg/kg | − | − | − | − | − | − | + | − | − |
| C57BL/6 | F | Group | 50 & 80 mg/kg | − | − | − | + | + | − | − | − | − | |
| M | Group | 45 mg/kg | − | − | − | + | − | + | − | − | − | ||
| 50 mg/kg | − | − | − | − | + | − | − | − | − | ||||
| Uns. | 50 mg/kg | − | + | + | − | − | + | − | − | − | |||
| Uns. | Uns. | 60 mg/kg | − | − | − | − | + | − | − | − | − | ||
| C57BL/6J | M | Single | 80 mg/kg | + | + | − | − | + | − | − | − | − | |
| Uns. | 45 mg/kg | − | − | − | − | + | + | − | − | − | |||
| 60 mg/kg | − | − | − | − | + | − | − | − | − | ||||
| Uns. | Uns. | 75 mg/kg | − | − | + | − | − | − | − | − | − | ||
| C57BL/6N | M + F | Uns. | 60 mg/kg | − | − | + | + | + | − | − | − | − | |
| KunMing | M | Group | 60 mg/kg | − | − | − | + | + | + | − | − | − | |
| Mixed | M | Single | 40–70 mg/kg | + | + | − | + | + | + | − | − | − | |
| Uns. | M | Uns. | 85 mg/kg | − | − | − | − | + | − | − | − | − | |
| Mature adult | C57BL/6SJL | F | Group | 40 mg/kg | − | − | − | − | + | − | − | − | − |
| C57BL/6 | M | Single | 50 mg/kg | − | + | + | − | + | − | − | − | − | |
| C57BL/6J | M | Single | 75 mg/kg | − | − | − | − | − | − | − | − | + | |
| M + F | Group | 60 mg/kg | − | − | − | + | − | − | − | − | − | ||
| Uns. | 50 mg/kg | − | + | + | + | − | + | − | − | − | |||
| Uns. | M | Uns. | 50 mg/kg | + | − | − | + | − | − | − | − | − | |
| 55 mg/kg | + | − | + | + | − | − | − | − | − | ||||
| Adult, uns. | Albino | M | Uns. | 105 mg/kg | − | + | − | − | − | − | − | − | − |
| C57BL/6 | M | Uns. | 30, 55, & 75 mg/kg | − | − | − | + | − | − | − | − | − | |
| C57BL/6S | M | Single | 50 mg/kg | − | − | − | + | + | + | − | − | − | |
| CD‐1 | F | Uns. | 60 mg/kg | − | − | − | − | − | − | − | + | − | |
| M | Uns. | 70 mg/kg | − | + | − | − | − | − | − | − | − | ||
| Mixed | M + F | Uns. | 50 mg/kg | − | + | − | + | − | − | − | − | − | |
| Uns. | Uns. | Uns. | 55 & 80 mg/kg | − | − | − | − | + | − | − | − | − | |
| NMRI | M | Group | 85 mg/kg | − | − | − | + | − | − | − | − | − | |
| Uns. | 60 mg/kg | + | − | − | − | − | − | − | − | − | |||
| Multiple ages | C57BL/6J | M | Group | 10–80 mg/kg | − | − | − | − | + | − | − | − | − |
| − | − | − | − | + | + | − | − | − | |||||
| Uns. | C57BL/6 | M | Single | 30 mg/kg | − | − | − | + | + | − | − | − | − |
| Uns. | Uns. | 50 mg/kg | − | − | − | − | + | − | − | − | − | ||
| C57BL/6J | Uns. | Single | 40 mg/kg | − | + | − | − | − | − | − | − | − | |
| 75 mg/kg | + | − | + | − | + | − | − | − | − | ||||
| Group | 40 mg/kg | − | − | − | + | − | + | + | − | − | |||
| Uns. | 75 mg/kg | − | − | + | − | − | − | − | − | − | |||
| CD‐1 | F | Single | 85 mg/kg | − | + | − | − | + | − | − | − | − | |
| M | Group | 65 mg/kg | + | − | + | − | − | − | − | − | − | ||
| Uns. | 60 mg/kg | + | − | + | − | + | − | + | − | − | |||
| 75 mg/kg | + | − | + | − | − | − | − | − | − | ||||
| 85 mg/kg | + | − | + | + | − | − | − | − | − | ||||
| ddY | M | Group | 100 mg/kg | − | + | − | − | − | − | − | − | − | |
| Mixed | Uns. | Uns. | 40 mg/kg | − | − | − | + | − | + | − | − | − | |
| Uns. | Uns. | Single | 40 mg/kg | − | − | − | − | − | − | − | + | + | |
| 50 mg/kg | + | − | − | + | − | − | − | − | − | ||||
| Uns. | 30 mg/kg | − | − | − | − | + | − | − | − | − | |||
| NMRI | M | Group | 89 mg/kg | − | + | − | − | − | − | − | − | − |
Abbreviations: EEG, Electroencephalogram; Sz, Seizure; Uns., Unspecified.
Pup: 0–3 weeks, Juvenile: 3–6 weeks, Young adult: 6–12 weeks, Mature adult: 3–6 months.
For example tonic seizures and myoclonic jerking.
That is latency, duration, or frequency.
For example Racine or other behavioral scoring.
That is a mathematical calculation of seizure threshold.
FIGURE 2Critical factors incompletely specified in PTZ‐related epilepsy papers. (A) Stacked column chart showing percentage of literature review papers that omitted 0, 1, 2, 3, or 4 of the critical factors identified (age, physiologic stressor, sex, and background). Findings are stratified based upon the route of PTZ administration (IP, IV, or SubQ). (B) Bar chart demonstrating the percentage of literature review papers that incompletely specified each critical factor.